Pifithrin-α (PFTα) HBr
别名: Pifithrin-α hydrobromide
目录号:S2929 Purity: 99.87%
Pifithrin-α (PFTα)是一种p53抑制剂,抑制p53依赖性的p53应答基因转录。Pifithrin-α也是一种有效的 aryl hydrocarbon receptor (AhR) 的兴奋剂。
CAS: 63208-82-2
客户使用Selleck的Pifithrin-α (PFTα) HBr发表文献128篇
- Signal Transduct Target Ther, 2022 7(1):290
- Cell Discov, 2022 8(1):49
- Am J Respir Crit Care Med, 2020 10.1164/rccm.202004-1274OC
- Nat Commun, 2024 15(1):10089
- Cell Death Differ, 2024 31(8):999-1012
- Int J Biol Sci, 2024 20(6):2008-2026
- Cell Mol Life Sci, 2024 81(1):101
- Cell Mol Life Sci, 2024 81(1):384
- Cell Mol Life Sci, 2024 82(1):14
- Phytomedicine, 2024 132:155876
- Cancers (Basel), 2024 16(20)3491
- Cancer Med, 2024 13(18):e70253
- J Cancer Res Clin Oncol, 2024 150(3):163
- Ren Fail, 2024 46(2):2365408
- Cell Death Dis, 2023 14(10):672
- iScience, 2023 26(7):107090
- Int J Mol Sci, 2023 24(20)15258
- J Virol, 2023 10.1128/jvi.01087-23
- Cancers (Basel), 2023 15(3)745
- Exp Cell Res, 2023 423(1):113451
- Evid Based Complement Alternat Med, 2023 2023:8378581
- Mol Ther, 2022 S1525-0016(22)00317-3
- J Exp Clin Cancer Res, 2022 41(1):130
- Haematologica, 2022 10.3324/haematol.2022.280879
- Cell Mol Gastroenterol Hepatol, 2022 14(6):1311-1331
- Cell Mol Gastroenterol Hepatol, 2022 S2352-345X(22)00063-7
- PLoS Pathog, 2022 18(3):e1010365
- Cells, 2022 11(16)2588
- Cells, 2022 11(4)712
- Commun Biol, 2022 5-1:889
- Int J Mol Sci, 2022 23(22)13867
- CNS Neurosci Ther, 2022 10.1111/cns.13821
- Dig Liver Dis, 2022 S1590-8658(22)00555-2
- Exp Cell Res, 2022 417(2):113231
- Tissue Cell, 2022 76:101802
- JACC Basic Transl Sci, 2022 7(4):366-380
- J Transl Med, 2021 19(1):374
- Oxid Med Cell Longev, 2021 2021:5986260
- Front Immunol, 2021 12:781680
- Br J Pharmacol, 2021 10.1111/bph.15385
- Cancer Gene Ther, 2021 10.1038/s41417-021-00385-7
- iScience, 2021 24(8):102837
- Mol Cancer Res, 2021 19(6):1051-1062
- Biochim Biophys Acta Mol Cell Res, 2021 1869(2):119174
- Eur J Pharmacol, 2021 907:174303
- Molecules, 2021 26(11)3108
- Development, 2021 dev.188276
- Molecules, 2021 26(11), 3108
- ACS Omega, 2021 6(15):10196-10206
- Toxicol In Vitro, 2021 73:105146
- Microvasc Res, 2021 138:104207
- Neurosci Lett, 2021 762:136134
- Ann Palliat Med, 2021 10(2):1578-1588
- Neuro Oncol, 2020 noaa207
- Biomed Pharmacother, 2020 133:110961
- Biomed Pharmacother, 2020 125:109948
- Br J Pharmacol, 2020 10.1111/bph.15350
- Cancers (Basel), 2020 20;12(2) pii: E493
- Aging (Albany NY), 2020 12(18):18649-18659
- Eur J Pharmacol, 2020 5;876:173056
- J Biol Chem, 2020 27;295(13):4237-4251
- J Steroid Biochem Mol Biol, 2020 198:105537
- Cell Biol Int, 2020 4
- BMC Complement Med Ther, 2020 20(1):94
- Toxicol Appl Pharmacol, 2020 387:114848
- Toxicol Lett, 2020 318:1-11
- Radiat Res, 2020 193(2):119-129
- Exp Biol Med (Maywood), 2020 1535370220961320
- Chin J Integr Med, 2020 10.1007/s11655-020-3098-3
- Biol Open, 2020 bio.51482
- Mol Cell, 2019 S1097-2765(19)30838-X
- J Clin Invest, 2019 1;129(11):4797-4816
- Redox Biol, 2019 22:101157
- Phytomedicine, 2019 53:124-133
- Stem Cell Res Ther, 2019 10(1):123
- Oxid Med Cell Longev, 2019 2019:7064319
- Br J Pharmacol, 2019 10.1111/bph.14916
- Arch Pharm Res, 2019 10.1007/s12272-019-01132-1
- Antioxid Redox Signal, 2019 30(12):1521-1538
- Artif Cells Nanomed Biotechnol, 2019 47(1):3720-3728
- Front Pharmacol, 2019 10:762
- J Virol, 2019 93(22)e01249-19
- J Neurosci, 2019 39(46):9107-9118
- Sci Rep, 2019 9(1):1897
- Oncol Rep, 2019 41(2):1075-1082
- Cancer Med, 2019 10.1002/cam4.2393
- J Cell Biochem, 2019 120(10):17067-17079
- Open Life Sci, 2019 14:262-274
- Redox Biol, 2018 15:253-265
- J Neuroinflammation, 2018 15(1):250
- J Cell Physiol, 2018 233(2):1312-1320
- Oncotarget, 2018 9(11):9907-9924
- Int J Oncol, 2018 53(3):1138-1148
- Front Mol Neurosci, 2018 11:403
- Sci Rep, 2018 8(1):13434
- Toxicol Appl Pharmacol, 2018 355:269-285
- Biomed Res Int, 2018 2018:1380146
- Biochem Biophys Res Commun, 2018 496(4):1183-1190
- Biochem Biophys Res Commun, 2018 504(1):123-128
- Exp Ther Med, 2018 16(2):643-648
- Acta Biomater, 2017 49:541-554
- Cell Rep, 2017 20(7):1692-1704
- Cell Prolif, 2017 10.1111/cpr.12319
- Cell Prolif, 2017 50(6)
- Oxid Med Cell Longev, 2017 2017:4082102
- Nanoscale, 2017 9(20):6765-6776
- Oncotarget, 2017 8(59):100691-100707
- Oncotarget, 2017 8(5):8622-8632
- Sci Rep, 2017 7(1):7599
- Sci Rep, 2017 7:43196
- J Periodontol, 2017 88(11):e200-e210
- Toxicol Appl Pharmacol, 2017 326:15-24
- Hum Mol Genet, 2017 26(17):3253-3270
- Biochem Biophys Res Commun, 2017 482(1):22-27
- Biochemistry, 2017 82(7):826-833
- Tumour Biol, 2017 39(6):1010428317703824
- Int J Biol Sci, 2016 12(11):1298-1308
- Cell Death Dis, 2016 7:e2188
- Int J Nanomedicine, 2016 11:6517-6531
- Oncotarget, 2016 7(43):69688-69702
- Int J Oncol, 2016 49(5):1973-1982
- J Biol Chem, 2016 291(9):4462-72
- Am J Transl Res, 2016 8(10):4040-4053
- Am J Transplant, 2015 15(12):3095-111
- Apoptosis, 2015 20(6):787-95
- Leuk Lymphoma, 2015 10.3109/10428194.2014.976819
- Int J Radiat Oncol Biol Phys, 2014 88(2):385-94
- Exp Cell Res, 2014 330(2):346-57
化学信息&溶解度
分子量 | 367.3 |
分子式 | C16H18N2OS.HBr |
CAS号 | 63208-82-2 |
Smiles | CC1=CC=C(C=C1)C(=O)CN2C3=C(CCCC3)SC2=N.Br |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 73 mg/mL ( 198.74 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 67 mg/mL ( 182.41 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 73 mg/mL ( 198.74 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 73 mg/mL ( 198.74 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 73 mg/mL ( 198.74 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:3.65mg/ml
(9.94mM)
操作示例:以 1 mL 工作液为例,取50μL73mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。